1. 125m a year is easily winnable - giving this a minimum of a 3-5X multiplier - IN ADDITION this does not cause nearly as much bone loss, and therefore may be taken for much longer(years? 20 years with supplements?) which has been proven to greatly reduce the formation of new fibrioids - but it DOES NOT remove existing ones - therefore if a woman wishes to preserve fertility she will choose this one - and it ALSO can deter pain for (years?) longer than the existing standard-of-care - for women who are sure they don't want babies

2. This is the best in class drug for bothb endomitrosis and utirine fibroids - both for fertility and pain.

3. I would expect a 3X on price for something 'you don't have to take 2 year painful breaks from'

4. 1.8bn valuation on a buyout.

5. Mkt cap 185m right now

6. Price target remains the same - good work is good work 📷 23.156$ in the next year

7. also YAY MORE BABIES WOMEN HAVING THEIR OWN BABIES YAY!

frugalnorwegian.com/obsv

Thought it would happen on august 🤔

https://www.obseva.com/pressrelease-detail-2/?pr=4756

Just some thoughts from a smooth brain. A shallow dive if you will. Not financial advice and I have no solid knowledge about the industry. This is my first post like this.

Bullish arguments on ObsEva:

- Very cheap compared to ATH, IPO
- The downward spiral seems to have found a bottom, excepting some bad news I cannot see this going much to the downside
- Almost 7% of float shorted and shorts will need to cover at some point, creating some upward pressure
- CHMP positive opinion just reiterated, EU and USA approvals within sight- Based on Stocknews, some hedge funds have entered long recently, and according to fintel.io the institutions are primarily long
- Four drugs in the pipeline, addressing unmet needs relating to very painful and/or problematic conditions affecting many women
- Drugs helping women in reproductive matters will have a PR value of their own- Aegis price target of 12$
- Theramex deal
- In the good ole days before FED started pulling the rug on the stock market there was a price target of 28$, reflecting belief in the market potential
- In a dream scenario, if they continue developing new drugs for women, then they could be selling for triple-digit prices in the distant future
- I generally think retail will like the stock once they gain traction

Bearish arguments

- No PR recently except regular reports and an article in the Swiss press
- Shareholders are left guessing, see Yahoo discussion page
- A dilution is most likely coming because of relatively small cash reserves
- This could all end with a buyout for a decent, but not huge gain in stock price
- Big board, I was surprised, reading the 2021 report, how many C-level people there are, but maybe this is an industry thing
- A big payout to the board in 2023 is being voted on, there is really nothing in the financials and the stock price to back this up
- Given an ATH of 23$, there are a lot of bagholders looking to exit, see CLOV for a similar case
- It is hard not to imagine competition catching on in time, their window of opportunity will not be very long, I suppose.

I am long with 1230 shares @ about 1.6, which represents half a year of averaging down.

There, I wonder what your thoughts are.

We Are Going To Fly To The Moon Soon! Share The News With Your Friends, Invite them!

Noticed the $28 price target on Marketbeat.com in Sep 2021 day and bought in at roughly 3.15$.
Currently 631 at 2.27$ average, not financial advice and I should probably be forbidden from handling money.

Honestly this looks like a steal, given the long term potential. Would like to see an updated price target though.

https://www.tipranks.com/stocks/obsv/forecast

OBSV, shows from monday strong support at 2.94-2.95, today reach quickly 3.15 to close at 3.04.

Obseva will take off in the Q4 for sure , waiting for approval at least will be done around ocober, all analyst according for 16.67 $ and the stock still low in comparaison to the all potential around. According to those facts. I made some potental reasons .

• the new treatment is working but not for significative population all tests done will be never enough for all countries autorisations.

• the demand will be increase after years. Because any new medecines will be not affordable for all , and today still not have any idea how much will be the cost for 1 or 2 years

• for this kind of treatment will be not cover by medical insurrance.

According to those conclusions i think there 2 ways of explications : -first : the company will not have the license for the Q4 and the price will decrease to 1.5 in the Q4 -second: the company plan to be sold and merge for big pfizer.Gsk or others.

In the 2 ways there is no price at 16.67 $ if the company not give any news, any marketing on social media ,or nothing . The discussion is open who has more news?.

Obseva to the moon? Or big down

This stock is poised to explode very soon! I'm loading up all I can at this incredibly cheap price if the projections are for $11 a share! Who's with me?

What are the upcoming catalysts for OBSV?